A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.
US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.
Actress, choreographer and "So You Think You Can Dance" judge Debbie Allen has signed on to participate with the drugmaker's type 2 diabetes awareness and wellness program.
The company expects to file an sNDA for plaque psoriasis next year.
Sales rose 5% compared to the same period last year.
Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also reaped blockbuster sales for Gilead.
Panel chair Randall Flick said QRxPharma "had not provided sufficient evidence to support a claim that Moxduo is safer than morphine or oxycodone."
But demand for Enbrel and Aranesp slipped.
The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.
The candidate would be the first to put oxycodone and morphine in one capsule.
AbbVie's all-oral HCV treatment filed off six Phase-III trials spanning 25 countries and 2,300 patients
Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.
The three drugmakers rearranged part of the pharma universe Tuesday with a string of pipeline-altering deals.
The deal would bring Allergan's Botox and Juvederm under the same roof as Restylane.
The rumored $101 billion bid would give Pfizer a foothold in imuno-oncology and diabetes.
Officials are asking users to change passwords, as an added precaution.
Physicians tell Leerink most of their patients are receiving the drug. Rejections tend to be over off-label use.
The company said it plans to file its rare-disease drug with the FDA later this year, for a 2015 review.
The Supreme Court denied Teva's request to keep branded Copaxone off the market while the appeals process shakes out.
The Las Vegas twosome give the anti-vaccination movement their signature treatment.
GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."
Pfizer and Teva's settlement puts generic Celebrex on the market by December.
Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.
The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.
Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.
The newly formed group will be known as Calcium with Steve Michaelson, formerly of Rosetta Wishbone, at the helm.
A District Court says Massachusetts cannot ban opioid painkiller Zohydro.
Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.
Medscape's survey of over 24,000 physicians found that a paycheck is not necessarily linked to a physician's professional satisfaction.
Centers for Disease Control data shows that diabetes complications including heart attack and amputation fell in the twenty years between 1990 and 2010. The bad news: the number of diagnosed diabetes patients tripled during that same time period.
Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.
Healthcare insurers seek to curb diabetes costs with interventions that may include house calls.
The drugmaker says the therapeutic approach has a narrow treatment potential.
Boehringer Ingelheim says it is no longer pursuing an interferon-free combination of faldaprevir and deleobuvir.
Roche also announced first-quarter sales shrank 1%.
The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.
New data from the International Liver Congress in London this past weekend showed strong efficacy for Gilead's Sovaldi and AbbVie's combo regimen when paired with ribavirin.
Poland joins the list of countries in which GlaxoSmithKline is accused of misconduct. Meanwhile, bioequivalence issues have prompted the FDA to revoke its approval of GSK's Wellbutrin generic.
A London court knocked down two Roche/Genentech patents, making a clearer path for biosimilars of the breast cancer drug. The primary patent lapses in July.
Politico calls her departure an "everybody wins" situation.
New leaders include Pfizer's Ian Read, Merck's Kenneth Frazier and Biogen Idec's George Scangos.
Physicians Desk Reference is on a mission to expand its image beyond just being that heavy book doctors consult for information
Complete data sets have prompted researchers to say Tamilflu and Relenza fail at their key reason for being: preventing flu pandemics.
Wednesday's coverage of doctor pay roiled physicians who say the CMS data set oversimplifies payment information and skews reality.
Phase-II results indicate Merck's all-in-one HCV oral could put pressure on Gilead.
CDM, the Omnicom network of healthcare agencies, named Josh Prince, previously the group's chief creative officer, to president. He replaces Carol DiSanto.
Facts tucked among the 9.2 million lines of data: 2% of doctors account for around 25% of Medicare billing.
23andMe cofounder Linda Avey is taking crowdsourced patient experiences to the web with a soft July launch of a platform called Curious.
Express Scripts said treatments for diabetes are the most expensive of the traditional medications, while specialty drugs are eating up a significant portion of total drug spend.
The FDA issued an official halt, five days after Halozyme stopped the Phase-II trial because of patient stroke information.
Researchers found a correlation between patients feeling involved and how well they stick—if they stick—to their medication regimens.
The drugmaker is accused of burying cancer risks associated with the diabetes medication.
The regulator has put off the inhaled insulin's PDUFA date by three months.
Phase-III results prompted the drugmaker to pursue a third-quarter filing.
Researchers find public service announcements and physician information don't change minds, but a California practice found one way it could.
Analysts say the Indianapolis, IN, drugmaker's Phase-I results show CDK 4/6 inhibitors will have a role in breast cancer treatment and that Pfizer's palbociclib will not clear the field.
The drugmaker said today that FDA has granted the company a Breakthrough Therapy designation and a priority review for its sofosbuvir/ledipasvir combo.
Sunday's data readout has divided the Street between the enthusiastic and the disappointed. The key reason: progression-free survival gains were not as high as anticipated.
The announcement will create the fifth largest generics drug maker, reports Reuters.
The Swiss drugmaker has scooped up Oryzon's experimental acute myeloid leukemia treatment and private Massachusetts diagnostics firm IQuum.
WSJ's sources say allegations of misconduct are similar to those leveled against the company in China.
Almost a week after announcing Baxter was going to break into two divisions, the Illinois company is already expanding.
Kaiser Permanente is swallowing the cost of Gilead's hepatitis C treatment Sovaldi, but is angry about the $84,000 cost.
The top 34 UK drug companies paid medical professionals around $64 million last year, for services that included speeches, medical study participation and third-party meeting sponsorships.
GlaxoSmithKline got some unwelcome attention from the FDA inspectors: a March 27 warning letter about unacceptable manufacturing and communications at a Cork, Ireland, manufacturing site where it found contamination issues.
A recent study shows that generic fill data, often used to promote the cost-savings associated with generic drugs, may hide the impact some health insurance plans have on patient medication use.
The ACA has spurred double-digit increases in demand for pharmaceuticals, new data suggest.
The GSK-Pfizer-Shionogi joint venture said it will add HIV med Tivicay to a United Nations patent pool, cutting its price for developing countries and granting access for generics firms.
The drugmaker is ceasing a trial called MAGRIT after it was unable to identify patients who could benefit from MAGE-A3.
Praised for helping navigate the shift by advertisers into digital, media vet Kim Kadlec is leaving pharma for a new role at AOL.
MannKind's inhalable insulin, a pipeline contender for 14 years, scored a near unanimous vote from an FDA advisory committee yesterday.
The FDA has issued draft guidance that funds FDA inspection of some drug compounders.
The Israel-based drugmaker will try to extend the MS treatment's patent life until September 2015.
The drugmaker saw positive results in demonstrating LDL reductions in Japanese patient populations.
A court granted Lilly six more years of patent protection for the almost $3-billion-dollar-a-year cancer drug.
At a hearing today, Public Citizen and the generics industry are sounding off on an FDA proposal that would allow generics firms to update labels, regardless of whether the brand has or hasn't.
Apollo EndoSurgery has tapped W2O Group as its agency of record for its LAP-BAND weight reduction system.
Detailed Phase-III results from several PCSK9 candidates confirm the clinical ability of the newest class of cholesterol-lowering treatments.
The drugmaker said successful results prompted an independent Data Monitoring Committee to recommend stopping the trial. The news follows an uneven week of pipeline drug news.
The FDA has approved a 24-hour version of Pfizer's heartburn medication.
The Carlyle Group has picked up Johnson & Johnson's Ortho Diagnostics for $4B.
A report indicates that Sovaldi's high price may hurt health-insurance investors.
The Bay State is saying no to the controversial prescription painkiller.
Phase-I tests show Novartis's ceritinib works on Xalkori-resistant patients.
The company, which expects a 9% to 10% sales jump in 2014, says it will split into two independent companies by the middle of next year.
Pfizer's investigational LDL-C lowering treatment bococizumab reduced LDL cholesterol in patients also taking statins.
Tampering concerns prompted the company's action.
Takeda's DPP-4 diabetes treatment, Nesina, showed no effect on CV mortality rates or hospitalization for heart failure in sub-analyses.
With just days before the enrollment deadline, courts are pulsing with legal opposition to heatlhcare reform insurance subsidies.
The March 31 deadline for health insurance is not the be-all-and-end-all, while a survey found that 50% of the uninsured intend to stay that way.
The regulator disputes findings that generic heart drugs made abroad were contaminated.
The three-year collaboration includes $1.5 million for chronic kidney disease research.
The company said it wants to wait for more data to come in.
A study by consulting firm Accenture shows that patients not only expect digital outreach, but that their desire to be engaged is consistently being ignored.
Merck has broadened its analytics approach to include team-ups with a slate of organizations at the intersection of Big Data and health IT.
Novartis's acute heart failure drug was not recommended for approval, according to an FDA advisory panel.
Flagging sales and patent expirations are keeping Lilly's pay rates static. AbbVie's CEO's paycheck reflects his new digs.
The professional association says it's necessary, because high prices do not indicate impact.
The UK's National Institute for Health and Care Excellence says it bounced Bayer's drug for failing to compare itself to current treatments, and Sanofi's over cost.
Analyses by Jefferies indicate that although doctors are interested in the experimental anti-cholesterol drugs, CV data will be a critical differentiator.